
OMGAQ
Healthcare · Biotechnology · $166,098 market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Analyst estimates aren’t available for this symbol.
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 14, 2024 | After the close | -0.27 | -0.30 | -11.1% |
| Aug 6, 2024 | Time not confirmed | -0.36 | -0.30 | +16.7% |
| May 6, 2024 | Time not confirmed | -0.33 | -0.36 | -10.2% |
| Mar 28, 2024 | Time not confirmed | -0.43 | -0.37 | +14.5% |
| Nov 9, 2023 | Time not confirmed | — | -0.40 | — |
| Aug 4, 2023 | Time not confirmed | — | -0.54 | — |
| May 4, 2023 | Time not confirmed | — | -0.50 | — |
| Mar 1, 2023 | Time not confirmed | — | -0.64 | — |
| Nov 8, 2022 | Time not confirmed | — | -0.54 | — |
| Aug 4, 2022 | Time not confirmed | — | -0.54 | — |
| May 5, 2022 | Time not confirmed | — | -0.42 | — |
| Mar 10, 2022 | Time not confirmed | — | -0.44 | — |
| Nov 10, 2021 | Time not confirmed | — | -0.39 | — |
Omega Therapeutics, Inc. operates as a clinical-stage biotechnology company. The company's OMEGA platform enables control of fundamental epigenetic processes to correct the root cause of disease by restoring aberrant gene expression to a range without altering native nucleic acid sequences. It also develops OTX-2002 for hepatocellular carcinoma; OTX-2101 for non-small cell lung cancer; omega epigenomic controllers…
| Sep 10, 2021 |
| Time not confirmed |
| — |
| -0.32 |
| — |